Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by Amundi

Amundi increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 168.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,979 shares of the biotechnology company’s stock after acquiring an additional 38,889 shares during the period. Amundi’s holdings in Ironwood Pharmaceuticals were worth $284,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Pacer Advisors Inc. boosted its position in Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after purchasing an additional 450,949 shares in the last quarter. State Street Corp lifted its position in shares of Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after acquiring an additional 677,024 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Ironwood Pharmaceuticals by 23.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after acquiring an additional 364,841 shares in the last quarter. FMR LLC lifted its position in shares of Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 34,089 shares in the last quarter. Finally, Weiss Asset Management LP purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $893,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, JMP Securities cut their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD opened at $1.41 on Friday. The company has a market cap of $225.64 million, a P/E ratio of -47.00 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a one year low of $1.34 and a one year high of $9.10. The business’s 50-day simple moving average is $2.27 and its 200 day simple moving average is $3.50.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The company had revenue of $90.55 million for the quarter, compared to analysts’ expectations of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. This trade represents a 6.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock worth $338,591 in the last 90 days. 12.90% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.